Literature DB >> 26219728

Genetic testing for BRCA1 and BRCA2 in the Province of Ontario.

A Finch1,2, M Wang3,4, A Fine1, L Atri3, S Khalouei3,4, M Pupavac3, B Rosen5, A Eisen2, C Elser6, G Charames3,4, K Metcalfe7, M C Chang3,4, S A Narod1, J Lerner-Ellis3,4,8.   

Abstract

In 2001, genetic testing for BRCA1 and BRCA2 was introduced in Ontario, for women at high-risk of breast or ovarian cancer. To date over 30,000 individuals have been tested throughout Ontario. Testing was offered to all Ontario residents who were eligible under any of 13 criteria. We report the results of tests conducted at Mount Sinai Hospital from 2007 to 2014. A total of 4726 individuals were tested, 764 (16.2%) were found to carry a pathogenic variant (mutation). Among 3684 women and men who underwent testing without a known familial BRCA mutation, 331 (9.0%) were found to carry a mutation. Among 1042 women and men tested for a known family mutation, 433 (41.6%) were positive. There were 603 female mutation carriers, of these, 303 were affected with breast or ovarian cancer (50%) and 16 with another cancer (2.3%). Of 284 unaffected female carriers, 242 (85%) were tested for a known family mutation and 42 (15%) were the first person in the family to be tested. By placing greater emphasis on recruiting unaffected female relatives of known mutation carriers for testing, greater than one-half of newly identified carriers will be unaffected.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BRCA1; BRCA2; breast cancer; genetic testing; ovarian cancer

Mesh:

Substances:

Year:  2015        PMID: 26219728     DOI: 10.1111/cge.12647

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  10 in total

1.  Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.

Authors:  Anita Y Kinney; Rachel Howell; Rachel Ruckman; Jean A McDougall; Tawny W Boyce; Belinda Vicuña; Ji-Hyun Lee; Dolores D Guest; Randi Rycroft; Patricia A Valverde; Kristina M Gallegos; Angela Meisner; Charles L Wiggins; Antoinette Stroup; Lisa E Paddock; Scott T Walters
Journal:  Contemp Clin Trials       Date:  2018-09-18       Impact factor: 2.226

2.  Recontacting clinical genetics patients with reclassified results: equity and policy challenges.

Authors:  Yvonne Bombard; Chloe Mighton
Journal:  Eur J Hum Genet       Date:  2019-04       Impact factor: 4.246

3.  Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario.

Authors:  Chloe Mighton; Conxi Lazaro; Jordan Lerner-Ellis; Nicholas Watkins; Vanessa Di Gioacchino; Andrew Wong; Martin C Chang; George S Charames
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-03       Impact factor: 4.553

4.  Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.

Authors:  Fan Zang; Xinyun Ding; Jiuan Chen; Li Hu; Jie Sun; Juan Zhang; Ye Xu; Lu Yao; Yuntao Xie
Journal:  Breast Cancer Res Treat       Date:  2022-08-16       Impact factor: 4.624

5.  The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada.

Authors:  Jacques Raphael; Sunil Verma; Paul Hewitt; Andrea Eisen
Journal:  J Genet Couns       Date:  2016-05-26       Impact factor: 2.537

6.  BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients.

Authors:  Lorena Incorvaia; Daniele Fanale; Marco Bono; Valentina Calò; Alessia Fiorino; Chiara Brando; Lidia Rita Corsini; Sofia Cutaia; Daniela Cancelliere; Alessia Pivetti; Clarissa Filorizzo; Maria La Mantia; Nadia Barraco; Stefania Cusenza; Giuseppe Badalamenti; Antonio Russo; Viviana Bazan
Journal:  Ther Adv Med Oncol       Date:  2020-12-16       Impact factor: 8.168

7.  Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.

Authors:  Eli Marie Grindedal; Cecilie Heramb; Inga Karsrud; Sarah Louise Ariansen; Lovise Mæhle; Dag Erik Undlien; Jan Norum; Ellen Schlichting
Journal:  BMC Cancer       Date:  2017-06-21       Impact factor: 4.430

8.  Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.

Authors:  Martin P Nilsson; Christof Winter; Ulf Kristoffersson; Martin Rehn; Christer Larsson; Lao H Saal; Niklas Loman
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

9.  Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes.

Authors:  Lorena Incorvaia; Daniele Fanale; Giuseppe Badalamenti; Marco Bono; Valentina Calò; Daniela Cancelliere; Marta Castiglia; Alessia Fiorino; Alessia Pivetti; Nadia Barraco; Sofia Cutaia; Antonio Russo; Viviana Bazan
Journal:  Cancers (Basel)       Date:  2020-05-05       Impact factor: 6.639

10.  Real-world health services utilisation and outcomes after BRCA1 and BRCA2 testing in Ontario, Canada: the What Comes Next Cohort Study protocol.

Authors:  Fahima Dossa; Maria C Cusimano; Rinku Sutradhar; Kelly Metcalfe; Tari Little; Jordan Lerner-Ellis; Andrea Eisen; Wendy S Meschino; Nancy N Baxter
Journal:  BMJ Open       Date:  2018-09-04       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.